Skip to main content
SpringerLink
Log in

Blutdrucksenker und pulmonale Karzinome

ACE-Hemmer und Lungenkrebsrisiko - eine kontroverse Debatte

  • Journal club
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Wu Z et al. Br J Cancer. 2023;128(2):168-76

  2. Batais M et al. Medicine (Baltimore). 2021;100(17):e25714

  3. Nguyen L et al. J Gastroenterol Hepatol. 2016;31(10):1773-82

  4. Wong CM et al. Cancer Epidemiol Biomarkers Prev. 2016;25(5):839-45

  5. Yusuf S et al. N Engl J Med. 2000;342(3):145-5

Download references

Author information

Authors and Affiliations

  1. Zentrum für Pneumologie und Thoraxchirurgie, Asklepios Lungenklinik Gauting, Robert-Koch-Allee 2, 82131, Gauting, Deutschland

    Daniel Hamberger Dr. med. univ.

Authors
  1. Daniel Hamberger Dr. med. univ.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hamberger, D. ACE-Hemmer und Lungenkrebsrisiko - eine kontroverse Debatte. InFo Hämatol Onkol 26, 29–30 (2023). https://doi.org/10.1007/s15004-023-0009-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-023-0009-8

Search

Navigation